Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh

Promotor: M. Danhof Co-promotor: O.E. Della Pasqua

Medical drugs are expensive to make and can have an adverse effect on the environment. Researchers Stefano Cucurachi and Justin Lian have developed a framework to help the healthcare system assess the economic and environmental sustainability of medical compounds.

Nuclear Magnetic Resonance (NMR) Spectroscopy is a non-destructive analytical technique that is used to study the nature and characteristics of molecules with an atomic level precision. It has a wide range of applications especially in synthetic chemistry, biological and biochemical research groups…

Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.

This thesis investigates a pharmacological challenge model induced by Toll-like receptor 7 (TLR7) activation, focusing on skin inflammation and its implications for early drug development.

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

Media in the Netherlands and abroad reported extensively about the drug research led by Leiden chemist Mario van der Stelt. In this research, Van der Stelt shows which unwanted side-effects a French drug candidate has.

Leiden chemists have developed a new technique with which they can determine the role of kinases – a group of proteins – in a living cell. This technique makes it easier to find new drug targets for diseases such as cancer and rheumatoid arthritis. The team published the findings in the journal Nature…

A team of five PhD students from Leiden University is in the running for first prize in the Pharmacometrics Skills Competition. In a drug development simulation, they apply their mathematical pharmacological skills to solve clinical problems. On 24 March they will compete in the finals in Orlando, F…

How do you know if a drug will actually work? The Leiden-based spin-off Omivera is developing a new technology that could provide clearer answers. The young company received a seed investment from the investment fund UNIIQ to support its development.

Professor of Clinical Pharmacology Adam Cohen from Leiden University received the prestigious Dr. Saal van Zwanenberg Honorary Prize on 12 November. The prize honours a scientist who has distinguished themselves in the field of research that has directly or indirectly led to the development of new medicines…

This thesis tackles the difficulty of predicting the liver’s clinical response to novel therapies, a challenge arising from interspecies differences and limitations of existing in vitro models.

Fascinated by science since high school, Alireza Mashaghi Tabari is driven to explore new ways of thinking in medicine. With a strong academic network, he educates students and gives public lectures. For his research at LACDR, he won the C.J. Kok Public Award 2018, making him the Faculty of Science's…

Mini organs-on-chips allow us to study how diseases develop and how drugs work. Although the technology is not new, it is becoming increasingly advanced. PhD candidate Bart Kramer hopes it will eliminate animal testing in the future.

The risk of a brain tumour recurring can be predicted more accurately by counting the number of immune cells in the tumour under a microscope. These are the findings from research conducted by LUMC, Erasmus MC and Heidelberg University.

One in two people will be diagnosed with cancer. World Cancer Day on 4 February raises awareness of the impact of this devastating disease. Leiden University is conducting various studies aimed at preventing and controlling cancer. Below are just a few examples.

Two consortia led by Leiden researchers have been awarded over one million euros by the Dutch Research Council and the Ministry of Health, Welfare and Sport to find solutions to antimicrobial resistance.

Professor Thomas Hankemeier and his international research team HYPERMARKER have received a 10m-euro grant from Horizon Europe and UK Research and Innovation.

Three Leiden researchers have been awarded a Vici grant by the Dutch Research Council. The funding of up to 1.5 million euros supports ‘talented, adventurous and pioneering researchers’. A total of 39 projects at Dutch institutions will receive a grant.

The antibiotic EVG7, developed in Leiden, has proven capable of fighting the dangerous gut bacterium C. difficile with only a minimal dose. What’s more, the bacterium is far less likely to return, a major issue with existing antibiotics. The research was published in Nature Communications.

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

Embryonic stem cells have the remarkable ability to develop into any type of cell. On their way to become for example a liver or a heart cell, they must repeatedly decide between alternative developmental paths. How they make these decisions is largely unknown. An international team of biophysicists…

RARE-NL, a new collaboration between university hospitals, hopes to find treatments for rare diseases. Professor Teun van Gelder is representing the LUMC in the initiative.

Bacteria carry countless hidden treasures in their DNA: fragments that could hold the key to new medicines. But how do you pick out the most promising ones from millions of options? ‘Look at the switches that turn genes on and off,’ says molecular biologist Gilles van Wezel.

The zebrafish is a promising vertebrate model organism in early drug discovery and development.

How can we prevent drug-induced liver and kidney damage? PhD candidates Marije Niemeijer and Lukas Wijaya investigated what happens in the cells during the onset of this damage: a stress response. Both focused on a different subtopic and made some interesting discoveries.

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

According to the LUMC, patients experience 30% fewer serious side effects when medication doses are tailored to their DNA.

Two Leiden researchers have been awarded ERC Proof of Concept grants. These grants, each worth EUR 150,000, will help the grantees in their efforts to bridge the gap from basic science to real-life applications

Leiden University and Leiden University Medical Center have joined the Netherlands Centre for One Health (NCOH), further strengthening the academic network in which such problems as antimicrobial resistance are studied.

Conference

Drug development critically depends on preclinical models that mimic human physiology, yet traditional two-dimensional cultures and animal models often lack predictive power.

Not taking into account the saturation of drug targets can lead to wrong conclusions about the duration of a drug's action. This is what former PhD candidate Wilbert de Witte writes together with the Leiden professors of pharmacology Meindert Danhof, Piet van der Graaf, and Liesbeth de Lange in Nature…

Researchers at Leiden University have made a breakthrough in the study of the hereditary Pompe disease. Together with colleagues in York, they have developed a molecule that binds to the enzyme that is key to the progress of the disease. The findings have been published in ACS Central Science.

It sounds futuristic, but it is possible: the creation of miniature organs of patients in order to study them and see how diseases develop and can be treated. This is what researchers from the LUMC, Twente University (UT), UMCG, TU Delft and the Hubrecht Institute hope to achieve in the next ten years…

The fact that scientists are increasingly better able to access molecular cell and tissue data also brings with it a new challenge: how can scientists find the information they need for research among the vast amount of data available?

Before patients can take a pill, scientists often spend years in the lab developing and testing a candidate drug. That often includes experiments with laboratory animals. As head of the rodent facility, Ilze Bot and her colleagues ensure that these experiments are conducted in an ethically responsible…

Leiden chemists have proposed a new model for enzymatic reactions, in which the flexibility of the substrate is much more important than previously thought. Their results are paradigm-shifting and could have major implications for drug research and enzyme engineering. Publication in Angewandte Chemi…

Edith Schippers, Minister of Health, will be investing six million euros over the coming four years to boost research on new antibiotics. The programme will be set up by several different parties, including the Leiden Centre for Antimicrobial Research.

Public funding for fundamental research is essential for innovation and the development of new medicines. This is demonstrated by Professor Science Based Business Simcha Jong and his colleague Hsini Huang after studying US federal funding restrictions for stem cell research under President George W.…

Medicines do not follow the one size fits all principle, because genetic differences can influence their efficiency. That is what research by PhD candidate Julia Hillger shows. She defends her PhD dissertation Take it Personal on Thursday 7 December.

Pharma company Janssen has begun construction on a new office and lab building at the Leiden Bio Science Park. The first pile of the 13,500 square metre building has been driven into the ground.

Not experiments and lab coats, but computers and artificial intelligence: this year's Nobel Prize in Chemistry went to the inventors of the groundbreaking AI model, AlphaFold. This programme accurately predicts protein structures based on their genetic code—a crucial step in understanding biological…

The Clinical Epidemiology department at the LUMC has set up a series of lectures for asylum seekers. The series has become a huge success.